We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients.
- Authors
Xiu-Shi Ni; Jiang Ouyang; Wen-Hui Zhu; Chong Wang; Bing Chen
- Abstract
Objective: To observe the efficacy and toxicity of autologous hematopoietic stem cell transplantation (HSCT) in progressive multiple sclerosis (PMS). Methodology: Twenty-one patients with PMS were treated with autologous HSCT. Stem cells were mobilized with cyclophosphamide (CY) and granulocyte colony-stimulating factor. After conditioning regimen of CY and total body irradiation or BEAM, stem cells were reinfused. CD34+ cell selection of the graft was performed and anti-thymocyte globulin was given for T-cell depletion. The probabilities of confirmed progression-free survival and disease activity-free survival were used to assess the efficacy and the adverse experiences were recorded to detect the toxicities. Results: The median follow-up time was 42 (6–65) months. The probabilities of confirmed progression-free survival and the disease activity-free survival were 75% and 33.3%, respectively. The principal adverse events included allergy, infection, elevation of liver enzymes, transient neurologic deterioration and depression. Two patients died of severe pneumonia and varicella-zoster virus hepatitis, at 4.5 and 15 months post-transplant, respectively. Conclusions: Autologous HSCT seems beneficial to PMS. However, more patients and longer follow up would be required to assess the risk/benefit ratio.
- Publication
Clinical Transplantation, 2006, Vol 20, Issue 4, p485
- ISSN
0902-0063
- Publication type
Academic Journal
- DOI
10.1111/j.1399-0012.2006.00510.x